EWM
CPRX

Evolution Wealth Management’s Catalyst Pharmaceutical CPRX Stock Holding History

Evolution Wealth Management’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.27K Hold
136
– – ﹤0.01% 728
2026
Q1 		$3.37K Hold
136
– – ﹤0.01% 679
2025
Q4 		$3.17K Buy
+136
New +$3.03K ﹤0.01% 601

Other funds holding CPRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Evolution Wealth Management's CPRX Position: Q2 2026 in Review

Evolution Wealth Management held its Catalyst Pharmaceutical (CPRX) position steady in Q2 2026 at 136 shares worth $4.27K. The position accounts for ﹤0.01% of the portfolio, ranked #728.

Evolution Wealth Management first reported a position in CPRX in Q4 2025 and has held it in 3 quarters since. 396 funds tracked by Wall St. Rank hold CPRX as of Q2 2026.

  • Evolution Wealth Management held 136 shares of Catalyst Pharmaceutical worth $4.27K as of Q2 2026.
  • Evolution Wealth Management left its Catalyst Pharmaceutical share count unchanged in Q2 2026.
  • Catalyst Pharmaceutical made up ﹤0.01% of Evolution Wealth Management's portfolio in Q2 2026, its #728 holding.
  • Evolution Wealth Management first reported a position in Catalyst Pharmaceutical in Q4 2025 and has held it in 3 quarters since.
  • 396 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2026.

Based on Evolution Wealth Management's 13F filing for Q2 2026, filed 21 Jul 2026.